EU safety committee reviews Deanxit and allergic reactions to some immunoglobulin batches
The European Medicines Agency's safety committee, the PRAC, met from 26 to 29 October 2026 and has opened a review of Deanxit, a depression and anxiety medicine combining flupentixol and melitracen. The review follows reports of serious movement, memory and thinking problems, some lasting after treatment stopped. The committee has also started examining a rise in allergic reactions linked to certain batches of normal human immunoglobulin, a blood-derived treatment used against infections and immune disorders.
This summary was generated by AI; the official source prevails.
What does it mean?
Deanxit, a medicine taken for depression and anxiety, is now under a fresh EU safety review because some patients had serious movement, memory and thinking problems. In France this combination is not authorised, so the review mainly matters for people who may have taken it abroad. Separately, some batches of a blood-derived treatment are being checked for causing more allergic reactions than usual.
Who is affected?
Patients who take or have taken Deanxit, and people receiving certain batches of normal human immunoglobulin treatment.